Phase II study of iproplatin in metastatic breast carcinoma.

Abstract

Thirty patients with progressive metastatic breast cancer and one prior chemotherapy regimen were treated with iproplatin at a starting dose of 300 mg/m2 iv every 3 weeks. After the first 11 patients, the starting dose was decreased to 270 mg/m2. There were one complete remission, three partial remissions, and two minor responses. Responses were observed in soft tissue and osseous and visceral areas. Grade 3 nausea and vomiting were observed in 38% of patients, and grade 3 diarrhea occurred in 31%. The dose-limiting toxicity was thrombocytopenia, which required dose de-escalation in 15 patients. No nephrotoxicity, neurotoxicity, or ototoxicity was observed. Iproplatin has modest antitumor activity in this group of previously treated patients with metastatic breast cancer.

• Authors: G N Hortobagyi, D Frye, F A Holmes, V Hug, G Fraschini, A U Buzdar
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 71 Issue 12 Pg. 1193-6 (Dec 1987) ISSN: 0361-5960 [Print] United States
• PMID: 3690529 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Organoplatinum Compounds
• iproplatin

Topics

• Adult
• Aged
• Breast Neoplasms (drug therapy)
• Carcinoma (drug therapy)
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Neoplasm Metastasis
• Organoplatinum Compounds (therapeutic use, toxicity)